AS
TEVA icon

Altshuler Shaham’s Teva Pharmaceuticals TEVA Stock Holding History

Altshuler Shaham’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,780
Closed -$1.26M – 544
2026
Q1 		$1.26M Buy
+4,780
New +$154K 0.02% 109

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Altshuler Shaham's TEVA Position: Q2 2026 in Review

Altshuler Shaham increased its Teva Pharmaceuticals (TEVA) stake by 8.8% in Q2 2026, buying an estimated $33.4M and bringing the position to 12,466,895 shares worth $412M. The position accounts for 5.12% of the portfolio, ranked #2.

Altshuler Shaham first reported a position in TEVA in Q4 2017 and has held it in 19 quarters since. 523 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Altshuler Shaham held 12,466,895 shares of Teva Pharmaceuticals worth $412M as of Q2 2026.
  • Altshuler Shaham bought 1,003,274 Teva Pharmaceuticals shares in Q2 2026, an estimated $33.4M.
  • Teva Pharmaceuticals made up 5.12% of Altshuler Shaham's portfolio in Q2 2026, its #2 holding.
  • Altshuler Shaham first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
  • 523 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Altshuler Shaham's 13F filing for Q2 2026, filed 12 Aug 2026.